Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for Primary Sjögren's Syndrome With Hematologic Involvement
ChiCTR2600118445Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in primary Sjögren's syndrome, sponsored by West China Hospital of Sichuan University. Primary endpoints: White Blood Cell Count, Platelet Count and 3 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2600118445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118445.